November 19, 2025 - Non-regulatory SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th
November 3, 2025 - Non-regulatory Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion
October 31, 2025 - Non-regulatory SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025
October 28, 2025 - Non-regulatory Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma
September 8, 2025 - Non-regulatory SynAct Pharma AB – Notification of Warrant and Share Transactions by Hunter Capital AB and Heights Capital Management
June 26, 2025 - Non-regulatory A majority of SynAct Pharma’s Board and management have acquired shares with a value of more than SEK 1 million
June 4, 2025 - Non-regulatory SynAct Pharma Refines Development Strategy for Lead Compound Resomelagon (AP1189)
May 12, 2025 - Non-regulatory SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy
April 23, 2025 - Non-regulatory SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy
April 16, 2025 - Non-regulatory SynAct Pharma to participate at BIO International Convention in Boston June 16-19
April 11, 2025 - Non-regulatory SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue
March 17, 2025 - Non-regulatory The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)
March 4, 2025 - Non-regulatory Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
December 17, 2024 - Non-regulatory SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco
November 27, 2024 - Non-regulatory SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
November 14, 2024 - Non-regulatory SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
September 23, 2024 - Non-regulatory SynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
September 13, 2024 - Non-regulatory SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence
August 30, 2024 - Non-regulatory First scientific publication showing treatment potential of a pro-resolving compound in human virus infection
July 1, 2024 - Non-regulatory SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
February 22, 2024 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis
January 30, 2024 - Non-regulatory SynAct Pharma expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors
October 3, 2023 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP
August 17, 2023 - Non-regulatory SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 20, 2023 - Non-regulatory SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 14, 2023 - Non-regulatory SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients
June 29, 2023 - Non-regulatory SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4
April 17, 2023 - Non-regulatory SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023
March 28, 2023 - Non-regulatory SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023
December 16, 2022 - Non-regulatory SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA
November 1, 2022 - Non-regulatory SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA
September 27, 2022 - Non-regulatory SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA
August 16, 2022 - Non-regulatory Resomelagon proposed international nonproprietary name (INN) for AP1189
July 21, 2022 - Non-regulatory SynAct Pharma improves the design of the ongoing Phase 2a study in iMN
April 1, 2022 - Non-regulatory SynAct publishes prospectus in connection with a fully guaranteed rights issue
December 1, 2021 - Non-regulatory SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office
November 19, 2021 - Non-regulatory SynAct Pharma announces Nomination Committee in respect of AGM 2022
November 11, 2021 - Non-regulatory SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
November 11, 2019 - Non-regulatory SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
February 25, 2019 - Non-regulatory John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB
June 18, 2018 - Non-regulatory SynAct Pharma AB responds to questions about the further development of candidate drug AP1189
April 17, 2018 - Non-regulatory SynAct Pharma AB holds investor meetings in connection with the rights issue
April 6, 2018 - Non-regulatory Market announcement 86/18 – Information about the rights issue for SynAct Pharma AB
December 9, 2016 - Non-regulatory SynAct Pharma submits application for start of Phase I clinical study
October 28, 2016 - Non-regulatory SynAct Pharma fulfilled its commitments to the financier Seed Fund CapNova by a one-time payment
July 11, 2016 - Non-regulatory Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today
July 4, 2016 - Non-regulatory Market Announcement 174/16 – SynAct Pharma AB listed on Aktietorget 11 July 2016 – corrected version
May 30, 2016 - Non-regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
May 24, 2016 - Non-regulatory Today the subscription period for SynAct Pharma AB’s issue opens, before the planned listing on Aktietorget
May 24, 2016 Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget
May 9, 2016 - Non-regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
